A detailed history of Verus Capital Partners, LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Verus Capital Partners, LLC holds 6,331 shares of BMY stock, worth $365,172. This represents 0.03% of its overall portfolio holdings.

Number of Shares
6,331
Previous 6,445 1.77%
Holding current value
$365,172
Previous $267,000 22.47%
% of portfolio
0.03%
Previous 0.03%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 04, 2024

SELL
$39.66 - $51.75 $4,521 - $5,899
-114 Reduced 1.77%
6,331 $327,000
Q2 2024

Aug 01, 2024

SELL
$40.25 - $52.99 $46,166 - $60,779
-1,147 Reduced 15.11%
6,445 $267,000
Q1 2024

May 07, 2024

BUY
$47.98 - $54.4 $41,310 - $46,838
861 Added 12.79%
7,592 $411,000
Q4 2023

Feb 09, 2024

BUY
$48.48 - $57.85 $26,809 - $31,991
553 Added 8.95%
6,731 $345,000
Q3 2023

Nov 01, 2023

SELL
$57.89 - $64.73 $22,519 - $25,179
-389 Reduced 5.92%
6,178 $358,000
Q2 2023

Jul 31, 2023

SELL
$63.71 - $70.74 $20,387 - $22,636
-320 Reduced 4.65%
6,567 $419,000
Q1 2023

May 09, 2023

SELL
$65.71 - $74.53 $985 - $1,117
-15 Reduced 0.22%
6,887 $477,000
Q4 2022

Feb 14, 2023

SELL
$68.48 - $81.09 $2,465 - $2,919
-36 Reduced 0.52%
6,902 $496,000
Q3 2022

Nov 14, 2022

SELL
$0.13 - $76.84 $17 - $10,373
-135 Reduced 1.91%
6,938 $493,000
Q2 2022

Aug 09, 2022

SELL
$72.62 - $79.98 $97,746 - $107,653
-1,346 Reduced 15.99%
7,073 $639,000
Q1 2022

Aug 09, 2022

SELL
$61.48 - $73.72 $447,021 - $536,018
-7,271 Reduced 46.34%
8,419 $645,000
Q1 2020

May 26, 2020

BUY
$46.4 - $67.43 $48,534 - $70,531
1,046 Added 7.14%
15,690 $875,000
Q4 2019

Feb 27, 2020

BUY
$49.21 - $64.19 $720,631 - $939,998
14,644 New
14,644 $940,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $123B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Verus Capital Partners, LLC Portfolio

Follow Verus Capital Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Verus Capital Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Verus Capital Partners, LLC with notifications on news.